Alexander A Klimenko and Sergey A Ivanov
Renal cell carcinoma (RCC) falls within the range of 2-3% of all oncology disorders in adults. Given the pathogenic mechanisms of RCC growth and dissemination, the disease is now actively treated by means of various types of the targeted therapy. One of the medicines available and widely used is Pazopanib which affects cancer cells in the form of inhibition of tyrosine kinase receptors. This article describes a case study of Pazopanib use in the course of treatment of inoperable RCC.
Partagez cet article
English 
Spanish 
Chinese 
Russian 
German 
Japanese 
Portuguese 
Hindi 